Exosome Diagnostic And Therapeutic Market-Industry Analysis, Market Size, Share, Trends, Growth And Forecast 2024-2030

Exosome Diagnostic and Therapeutic Market Overview

Exosome Diagnostic and Therapeutic Market size is estimated to reach $1.2 billion by 2030, growing at a CAGR of 30% during the forecast period 2024-2030. Exosomes transfer the DNA, RNA, and proteins to different cells in the body. It is related with viral pathogenicity, immune responses, cancer progression, and cardiovascular diseases. Exosomes helps in regulating complex intracellular and extracellular vesicles, hepatocellular carcinoma pathways that are advanced in their usefulness in the therapeutic control of several neurodegenerative conditions and cancer. Increasing research activities in exosome therapeutics and growing incidences of the chronic diseases such as cancer are the major factors driving the growth of the market. Rising income levels, increasing development in the healthcare sectors, and technological advancements is set to further enhance the overall market development of the Exosome Diagnostic and Therapeutic Market for the period 2024-2030.

There's a growing interest in exosome-based diagnostics, offering non-invasive methods for disease detection and monitoring. Exosome therapeutics are becoming a focus area in regenerative medicine, holding promise for treating various conditions, including tissue damage and neurodegenerative diseases. Advancements in exosome isolation and purification techniques enhance their therapeutic potential and scalability. Fourthly, exosome-based drug delivery systems are revolutionizing targeted therapies, offering precise delivery of therapeutic payloads. Exosome research is expanding to explore their role in intercellular communication and disease pathogenesis, opening new avenues for discovery and innovation are a few factors set to drive the growth of the Exosomes Industry for the period 2024-2030. 

Market Snapshot :-

Report Coverage:

The report: “Exosome Diagnostic and Therapeutic Market Forecast (2024-2030)”, by Industry ARC, covers an in-depth analysis of the following segments of the Exosome Diagnostic and Therapeutic Market. 
By Product: Apparatuses, Gears, and reactant/reagents.
By Cancer Application: Kidney cancer, Thyroid cancer, Prostate cancer, HCC (= Hepatocellular carcinoma) liver cancer, Breast cancer, lung cancer, Throat cancer 
By End User: Hospitals, Pharmaceutical Firms, Research Bodies/Institutions, Testing Clinics
By Application: Diagnostic, and Therapeutic.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways:

• Geographically, the North America Exosome Diagnostic and Therapeutic Market accounted for the highest revenue share in 2023 and it is poised to dominate the market over the period 2024-2030 owing to the rise in awareness about the presence of state-of-the-art research laboratories. Furthermore, the countries such as Canada and USA allocate up to 18-20% of their budget for medical development and advancements.
• The increase in the prevalence of cancer, and exosomes application in curing it is driving the Exosome Diagnostic and Therapeutic Market. However, rigorous government protocols such as consent for the practice of exosomes as curative reagents are one of the major factors that are said to reduce the growth of the Exosome Diagnostic and Therapeutic Market.
• Detailed analysis on the strength, weaknesses, and opportunities of the prominent players operating in the market will be provided in the Exosome Diagnostic and Therapeutic Market report.

For more details on this report - Request for Sample

Exosome Diagnostic and Therapeutic Market Segment Analysis-By Cancer Application

The Exosome Diagnostic and Therapeutic Market based on the Cancer Application can be further segmented into Kidney cancer, Thyroid cancer, Prostate cancer, HCC (= Hepatocellular carcinoma) liver cancer, Breast cancer, lung cancer, Throat cancer. The lung cancer segment held the largest share in 2023 owing to the factors such as an upsurge in cases of lung cancer due to expansion in the smoking trend among youngsters, increasing pollution. As per the AQI index of various countries, predominant regions have AQI above 101, a pre-approved standard by WHO for a disease-free life. However, as per the latest data study, countries such as India have 20 states who have the AQI index termed “really poor.” Owing to such trends worldwide, the segment took hold.

Lung cancer along with the throat and liver segment is estimated to be the fastest-growing segment with a CAGR of 31% over the period 2024-2030. This growth is owing to factors such as wide-spreading cases of the above-mentioned types of cancers, upsurging poor ingestion habits of people, swelling usage of alcohol to deal with depression, Increase in funding by the government and institutions in the field of research and development. 

Exosome Diagnostic and Therapeutic Market Segment Analysis-By End User

The Exosome Diagnostic and Therapeutic Market based on the End User can be further segmented into Hospitals, Pharmaceutical Firms, Research Bodies/Institutions, Testing Clinics. The Research Bodies/Institutions segment held the largest share in 2023 owing to the factors such as the innumerable amount of capital into research and developments of various contemporary tools and techniques which will help in isolating exosomes, breakthroughs in the discovery of drugs. For example, R&D costs for Incyte increased by 8.2% to $1.7 billion in the year that ended September 30, 2023. Additionally, the companies have been outsourcing a major chunk of research pertaining activities, which has further allowed them to hold a position.

Moreover, the research bodies segment is estimated to be the fastest-growing segment with a CAGR of 31% over the forecast period 2024-2030. This growth is owing to sweeping enlargement in cancer patients which is fuelling the demand for advanced tools and techniques for research purposes, increasing trend of digitalization in developed as well as developing countries, liberty to research institutes by the government bodies to conduct their research obstruction-free, Heavy flows of capital/investment to strike breakthroughs.

Exosome Diagnostic and Therapeutic Market Segment Analysis-By Geography 

The Exosomes based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 35% of the overall market in 2023. The growth in this segment is owing to the factors such as affluent economy ensuing innumerable amounts of hard cash into setting up research laboratories with world-class facilities, presence of premier institutions like MIT, Harvard, etc., surfeit flows of cash into research and development. Additionally, the US government pertains to providing close to 5% of the annual medical budget for R&D purposes, which helps the market to space.

However, the Asia-Pacific segment is estimated to be the fastest-growing segment over the period 2024-2030. This growth is owing to factors such as increment in cancer patients, colossal population, prospering GDPs of developing nations like Vietnam, Indonesia, India, and China ensuring a substantial amount of riches into health infrastructure, and research and development. 

Exosome Diagnostic and Therapeutic Market Drivers

The technological breakthrough in isolating exosomes and other practices are Projected to Drive Market Growth. 

According to the Pan American Health Organization (PAHO) 2023, there are around 20 million diagnosed cases of cancer and approximately 10 million deaths occurred worldwide. Therefore, as the prevalence of various types of cancer is escalating various researchers around the world are putting their valuable efforts into fabricating useful tools and techniques. Nowadays, exosomes are being extracted from the milk of cows as they have proved their worth in curing breast and lungs cancer. Therefore, the demand for using exosomes in medical treatments is swelling.

Enlarging population and cases of cancer Expected to Boost Product Demand.

The global population is on swell especially the elderly population. According to WHO study 2022; In 2030, one-sixth of the global population will be 60 years or older, marking an increase from 1 billion in 2020 to 1.4 billion. By 2050, the population of individuals aged 60 and above is projected to double, reaching 2.1 billion. Furthermore, the number of those aged 80 or older is anticipated to triple, reaching 426 million by 2050, compared to the figures in 2020. Old age isn’t always soothing. Ofttimes, it comes with a profusion of maladies such as diminished immunity and problems like cancer finding a home easily inside the body which is eventually stimulating the demand for Exosome Diagnostic and Therapeutic Market. The estimates vary, but a failed trial can cost somewhere between $800 million to $1.4 billion.

Exosome Diagnostic and Therapeutic Market Challenges

Stringent govt policies, In-depth knowledge is Anticipated to Hamper Market Growth.

Sometimes, getting approval from government bodies for newly manufactured techniques and drugs becomes a big headache for pharmaceutical companies and takes a lot of time. On top of that, isolating exosomes isn’t an easy process. It demands an adequate amount of time, an innumerable amount of funds, laboratories with world-class facilities, and skilled labor. Therefore, the lack of skilled professionals in the field is estimated to cripple the growth of the Exosome Diagnostic and Therapeutic Market. Additionally, a lot of costs go on if a trial fails at a given stage.

Exosome Diagnostic and Therapeutic Market Competitive Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in this market. Exosomes top 10 companies include:

1. Danaher Beckman Coulter Inc.
2. QIAGEN
3. ExoDx
4. MBL International
5. Novus Biologicals
6. Lonza
7. System Biosciences
8. Miltenyi Biotec
9. Thermo fisher scientific inc.
10. Everzom

Partnerships/Product Launches: 

• In June 2023, Evox Therapeutics Ltd acquired Codiak Biosciences' engEx-AAV™ technology platform, securing exclusive rights to engineering and manufacturing, enabling active loading of adeno-associated virus (AAV) into exosomes for enhanced delivery and expression in pre-clinical models, while shielding from neutralizing antibodies. 

For more Lifesciences and Healthcare Market reports, please click here